Liver function and drug levels: a new study on repotrectinib
NCT ID NCT06352528
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 32 times
Summary
This study looked at how a single dose of the drug repotrectinib stays in the blood of people with moderate or severe liver impairment compared to healthy volunteers. 18 adults participated, and researchers measured drug levels and checked for side effects. The goal was to understand how liver function affects the drug, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Orlando Clinical Research Center
Orlando, Florida, 32809-3017, United States
-
Panax Clinical Research
Miami Lakes, Florida, 33014-2811, United States
-
The Texas Liver Institute, Inc.
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.